v3.25.2

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current Assets:
Cash and cash equivalents	$ 22,047	$ 19,926
Investment in marketable securities	17,600	41,590
Prepaid and other current assets	4,696	2,921
Total Current Assets	44,343	64,437
Non-current Assets:
Property and equipment, net	102	113
Operating lease right-of-use assets	32	93
Non-current prepaid expenses and other assets	241	2,262
Total Non-current Assets	375	2,468
Total Assets	44,718	66,905
Current Liabilities:
Trade payables	1,414	2,707
Accrued expenses	3,578	9,272
Employee related obligations	819	1,428
Operating lease liabilities	25	99
Other current liabilities	0	1,313
Total Current Liabilities	5,836	14,819
Total Liabilities	5,836	14,819
Commitments and Contingencies
Stockholders' Equity:
Preferred stock: $0.0001 par value; 20,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024	0	0
Common stock: $0.0001 par value; 150,000,000 shares authorized at June 30, 2025 and December 31, 2024; 19,773,784 and 14,830,013 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	2	1
Additional paid-in capital	784,418	783,235
Accumulated other comprehensive (loss) income	(2)	20
Accumulated deficit	(745,536)	(731,170)
Total Stockholders' Equity	38,882	52,086
Total Liabilities and Stockholders’ Equity	$ 44,718	$ 66,905

Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

VYNE Therapeutics Inc. 10-Q